Medical News

RSS

Will health care savings be used to reduce the deficit?

Kaiser Health News staff writer Mary Agnes Carey writes: "In their effort to overhaul the health system, President Barack Obama and congressional Democrats pressed hospitals, drug makers and other providers to accept billions of dollars in government payment cuts and new fees to help finance the legislation.

16 Feb 2010

Adding rosemary extracts in ground beef can reduce cancer-causing agents

The addition of rosemary extract to ground beef actually reduces cancer-causing agents that can form upon cooking, according to a recent study in the Journal of Food Science, published by the Institute of Food Technologists.

16 Feb 2010

AB SCIEX acquires liquid chromatography business of Eksigent Technologies

AB SCIEX, a global leader in life science analytical technologies, today announced that it has acquired the liquid chromatography business of Eksigent Technologies. This acquisition significantly strengthens AB SCIEX’s position in liquid chromatography, which is a key technology used frequently in a broad range of life science applications such as protein biomarker research, drug discovery and basic research.

16 Feb 2010

Advice on decoding and correcting medical bills

The Los Angeles Times offers advice to consumers on how to understand and correct medical bills.

16 Feb 2010

New program launched for HIV-positive men

The nation's largest surrogacy agency announced today that the number of babies born to HIV-positive clients is expected to more than double in 2010 as its program for HIV-positive men using their own sperm to create embryos continues to expand in the U.S. and abroad.

16 Feb 2010

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2009.

16 Feb 2010

Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial

Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process.

16 Feb 2010

Palatin Technologies announces net income of $4.5M for second-quarter fiscal 2010

Palatin Technologies, Inc. today announced results for its second quarter ended December 31, 2009. Palatin reported net income of $4.5 million, or $0.04 per basic and diluted share, for the quarter ended December 31, 2009, compared to a net loss of $0.4 million, or $0.00 per basic and diluted share, for the same period in 2008. Total revenues in the quarter ended December 31, 2009 were $7.3 million, compared to $1.2 million for the same period in 2008.

16 Feb 2010

Derycz Scientific reports second-quarter and half-year fiscal 2010 results

Derycz Scientific, a company that is pioneering a fresh way of facilitating the flow of information from content publishers to enterprise customers and their constituents, announced its second quarter and half-year financial results for fiscal year 2010.

16 Feb 2010

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

EntreMed, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).

16 Feb 2010

AGA Medical Holdings announces fourth-quarter and full-year 2009 financial results

AGA Medical Holdings, a leading developer of interventional medical devices for the minimally invasive treatment of structural heart defects and vascular abnormalities, today reported financial results for the fourth quarter and full year ended Dec. 31, 2009.

16 Feb 2010

MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial

MAP Pharmaceuticals, Inc. today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

16 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

Delcath Systems to initiate Expanded Access Program for melphalan in patients with metastatic melanoma to the liver

Delcath Systems, Inc., which is testing its proprietary treatment system for metastatic cancers to the liver, announced today that the U.S. Food and Drug Administration ("FDA") will allow the Company to initiate an Expanded Use – Intermediate Size Population protocol for the hepatic arterial infusion of melphalan with venous filtration via the Delcath PHP System™ for patients with ocular and cutaneous melanoma metastatic to the liver.

16 Feb 2010

Childhood obesity: Strongest predictor of premature death

In a study now being published in The New England Journal of Medicine, Associate Professor Paul Franks of Umeå University in Sweden, in collaboration with researchers in the US, shows how childhood obesity, together with other risk factors for cardiovascular disease, affects premature death.

16 Feb 2010

WellPoint cancels Investor Day, schedules conference call to review 2010 financial outlook

WellPoint, Inc. today cancelled its Investor Day previously scheduled for February 23, 2010, and announced that management will review the Company's 2010 financial outlook during a conference call on March 17, 2010, at 8:30 a.m. Eastern Daylight Time (EDT). The Company continues to expect full year 2010 net income to be at least $6.00 per share, subject to its ability to secure and maintain sufficient premium rates.

16 Feb 2010

EVOLVE WELLNESS CENTER expands to prominent new space in West Hollywood

EVOLVE WELLNESS CENTER, Los Angeles’ premier Acupuncture group for more than 13 years has expanded to a prominent new space in West Hollywood and is planning to celebrate its Grand Re-Opening with a great deal of fanfare.

16 Feb 2010

First Edition: February 16, 2010

Today's health policy headlines cover a range of topics -- from using health savings to reduce the deficit to how tort reform fits into the current health reform negotiations.

16 Feb 2010

Effects of eco-toxicology on Zebra fish

Rasoul Nourizadeh-Lillabadi has shown that zebra fish can be used as models in order to study the effects of eco-toxicology on fish indigenous to Norway. The toxic substances used in the research project come from water effluent from the offshore industry and from organic material that had accumulated in the liver of burbot fish in the lakes of Mjøsa and Losna.

16 Feb 2010

NACHC: ARRA investment is making a difference in community health centers

People and communities are healthier thanks to the investment in America’s Health Centers from the American Recovery and Reinvestment Act (ARRA), or the “economic stimulus.” The law, enacted one year ago this week, provided funds that helped health centers expand care to the growing numbers of jobless and uninsured people who were quickly filling up their waiting rooms.

16 Feb 2010